Icon

SUNLENCA (NDA215973)- (EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML))

LENACAPAVIR SODIUM GILEAD SCIENCES INC
EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML)
No No
2041-Jun-04 2027-Dec-22
None None
None No
SUNLENCA, a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, in combination with other antiretroviral(s), is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.